JP2004519453A5 - - Google Patents

Claims (8)

Reduces the possibility of causing inflammation of immunogenic nucleic acids, especially GpG-ODN, and / or lipopolysaccharide, administered subcutaneously, intramuscularly, intradermally or transdermally Use of polycationic compounds for the purpose. 2. Use according to claim 1, wherein the administered immunogenic nucleic acid and / or lipopolysaccharide further comprises an antigen . Use according to claim 2 , wherein the antigen is selected from the group consisting of antigens from viral or bacterial pathogens, antigens from eukaryotic pathogens, tumor antigens, autoimmune antigens or mixtures thereof. Use according to any of claims 1 to 3 , wherein the polycationic compound is a polycationic peptide, preferably a basic polypeptide, an organic polycation containing peptide bonds, or a mixture thereof. 2. The polycationic compound is polylysine, polyarginine, a polypeptide comprising more than 50% basic amino acid residues in the range of more than 5, especially more than 10 amino acid residues, or a mixture thereof. Use according to any of 4 to 4 . The immunogenic nucleic acid and / or lipopolysaccharide to be administered is an inosine-containing ODN (I-ODN) The use according to any of claims 1 to 5 , further comprising: Immunogenic nucleic acids and / or lipopolysaccharides for the administration Ru is administered as a pharmaceutical or vaccine act locally, The use according to any one of claims 1 to 6. The use according to any one of claims 1 to 7 , wherein the administered immunogenic nucleic acid and / or lipopolysaccharide further comprises an active substance, and the active substance has an affinity for the polycationic compound.